It contains information on key terms, activities prohibited by the Wholesaling provision, activities not prohibited, inspections and regulatory or enforcement action.
Electronic or written comments on the draft guidance should be submitted on or before August 28, 2023, to ensure that the Agency considers the comment on this draft guidance before it begins work on the final version of the guidance.
Contact RegASK to know more about regulation changes in the US.
Read Pharma and Biotech Industry case studies
The post US FDA Provides Recommendations on the Statutory Prohibition on Wholesaling for Certain Compounded Drugs appeared first on RegASK.
